Literature DB >> 20110914

Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.

Frank Boxberger1, Heinz Albrecht, Peter C Konturek, Udo Reulbach, Gudrun Maennlein, Thomas Meyer, Werner Hohenberger, Eckhart G Hahn, Axel Wein.   

Abstract

BACKGROUND: In 2003 Wein et al. published data after a short median follow up (23 months). Here we report on the long-term results. MATERIAL/
METHODS: The patients (n=20) received a neoadjuvant treatment regimen comprising biweekly 85 mg/m2 oxaliplatin (L-OHP) (2h-infusion, d 1, 15, 29 qd 57) and 500 mg/m2 calcium folinic acid (FA) (1-2h-infusion, d 1, 8, 15, 22, 29, 36 qd 57) followed by 2600 mg/m2 5-Fluorouracil (5-FU) (24h-infusion, d 1, 8, 15, 22, 29, 36 qd 57). Two cycles of chemotherapy were administered, with a third being added when the treatment was well tolerated. Thereafter, curative resection of the liver metastases was attempted.
RESULTS: After neoadjuvant therapy, imaging procedures revealed complete remission in 2 patients (10%) and partial remission in 18 patients (90%). Diarrhea (Common Toxicity Criteria toxicity grade 3) was observed in 6 patients (30%) as main symptom of toxicity, followed by vomiting in 3 patients (15%). Higher grade sensomotoric neuropathy did not present. The curative resectability rate (R0) was 80%. In 9 out of 18 patients (50%) undergoing surgical intervention minor postoperative complications occurred. No postoperative mortality was observed. Over a median follow up of 45,5 months the median survival of all patients is 3.0 years and the 5-year overall survival rate is 40%. The 5-year disease-free survival rate is 25%.
CONCLUSIONS: Neoadjuvant treatment with 5-FU combined with FA and L-OHP proved to be highly effective and well tolerated. Disease-free survival rates and median overall survival rates are promising.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20110914

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  6 in total

1.  Thermal ablation of unresectable liver tumors: factors associated with partial ablation and the impact on long-term survival.

Authors:  Philipp Wiggermann; Ralf Puls; Andrej Vasilj; Dominik Sieroń; Andreas G Schreyer; Ernst-Michael Jung; Wojciech Wawrzynek; Christian Stroszczynski
Journal:  Med Sci Monit       Date:  2012-02

2.  Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells.

Authors:  Ding-pei Han; Qian-lin Zhu; Jiang-tao Cui; Pu-xiongzhi Wang; Shun Qu; Qi-feng Cao; Ya-ping Zong; Bo Feng; Min-hua Zheng; Ai-guo Lu
Journal:  Med Sci Monit       Date:  2012-06

3.  Diagnosis-specific graded prognostic assessment score is valid in patients with brain metastases treated in routine clinical practice in two European countries.

Authors:  Carsten Nieder; Nicolaus H Andratschke; Hans Geinitz; Anca L Grosu
Journal:  Med Sci Monit       Date:  2012-07

Review 4.  A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.

Authors:  Yi Li; Ji Wang; Xiaowei Ma; Li Tan; Yanli Yan; Chaofan Xue; Beina Hui; Rui Liu; Hailin Ma; Juan Ren
Journal:  Int J Biol Sci       Date:  2016-07-17       Impact factor: 6.580

5.  Prognostic importance of some clinical and therapeutic factors for the effect of portal vein embolization in patients with primarily inoperable colorectal liver metastases.

Authors:  Vladislav Treska; Tomas Skalicky; Alan Sutnar; Liska Vaclav; Jakub Fichtl; Judita Kinkorova; Monika Vachtova; Andrea Narsanska
Journal:  Arch Med Sci       Date:  2013-02-21       Impact factor: 3.318

6.  Colorectal cancer mortality in Poland - analysis of regional variation.

Authors:  Alicja Klimczak; Bogumiła Kempińska-Mirosławska; Michał Mik; Lukasz Dziki; Adam Dziki
Journal:  Arch Med Sci       Date:  2012-05-13       Impact factor: 3.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.